226249-02-1

Basic information

• Product Name: (R)-1-(4-chlorobenzyl)-3-(glycylamino)pyrrolidine
• Synonyms: (R)-1-(4-chlorobenzyl)-3-(glycylamino)pyrrolidine
• CAS NO: 226249-02-1
• Molecular Weight: 267.758
• Mol File: 226249-02-1.mol

Chemical Properties

• CAS DataBase Reference: (R)-1-(4-chlorobenzyl)-3-(glycylamino)pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(4-chlorobenzyl)-3-(glycylamino)pyrrolidine(226249-02-1)
• EPA Substance Registry System: (R)-1-(4-chlorobenzyl)-3-(glycylamino)pyrrolidine(226249-02-1)

Safety Data

• Hazardous Substances Data: 226249-02-1(Hazardous Substances Data)

Upstream product

• 226249-00-9 (R)-3-{N-(tert-butoxycarbonyl)glycyl}amino-1-(4-chlorobenzyl)-pyrrolidine 

Downstream Products

• 226226-27-3 C₂₁H₂₁ClF₃N₃O₂ 
• 226226-40-0 C₂₁H₂₄ClN₃O₂ 
• 226226-86-4 C₂₀H₂₁ClN₄O₄ 
• 226226-56-8 C₂₀H₂₁Cl₂N₃O₂ 
• 226226-61-5 C₂₀H₂₁Cl₂N₃O₂ 
• 226226-42-2 C₂₀H₂₁Cl₂N₃O₂ 
• 1025727-51-8 C₂₀H₂₂ClN₃O₂ 
• 226226-34-2 C₂₁H₂₄ClN₃O₃ 
• 226226-65-9 C₂₁H₂₄ClN₃O₂ 
• 226226-50-2 C₂₁H₂₁ClF₃N₃O₃ 
• 226226-64-8 C₂₁H₂₁ClF₃N₃O₂ 
• 226226-28-4 C₂₀H₂₁BrClN₃O₂ 
• 226226-30-8 C₂₀H₂₁ClFN₃O₂ 
• 226226-45-5 C₂₁H₂₁ClN₄O₂ 

Relevant articles and documents

Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series

SAR studies were conducted around lead compound 1 using high-throughput parallel solution and solid phase synthesis. Our lead optimization efforts led to the identification of several CCR2b antagonists with potent activity in both binding and functional a

CYCLOAMINE CCR5 RECEPTOR ANTAGONISTS

Remedies or prophylactics for diseases in association with CCR5 such as AIDS, rheumatoid arthritis or nephritis comprising a cyclic amine compound represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof or a phar

CYCLIC AMINE CCR3 ANTAGONISTS

A medicine containing, as an active ingredient, a cyclic amine derivative represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1 to C6 alkyl addition sal

REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES

This invention provides remedies or prophylactics for diseases in association with chemokines such as MIP-1 α and/or MCP-1. Namely, remedies or prophylactics for diseases in association with the chemokines such as rheumatoid arthritis or nephritis contain

Cyclic amine derivatives and their use as drugs

A compound represented by the general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6alkyl addition salt thereof, and their medical applications. These compounds inhibit the action of chemokines such as MIP-1α and/or MCP-1 on target cells, and are useful as therapeutic and/or preventative drugs in diseases, such as atheroclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.